Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
British retailers have reported their strongest seasonal sales in more than four years in June, according to the CBI. The easing of lockdown restrictions on shops and the hospitality industry in England and Wales, coupled with growing confidence in going out as the vaccination programme continues apace, fuelled the strongest sales since November 2016.
https://www.theguardian.com/business/2021/jun/25/uk-retailers-report-strongest-seasonal-sales-in-four-years
Worth a read if anyone missed it: https://www.yugroupplc.com/wp-content/uploads/2021/03/Yu-Group-PLC-Annual-report-and-financial-statements-2020.pdf
More questions than answers as is the norm you have to ask why the covid update wasn’t worthy of its own RNS is the data really not that compelling look at Pfizer’s PF 07321332 that’s grabbed the headlines today. Hopefully there will be some good investor questions put forward this week.
No reason to hold back positive news, if its another failed attempt at MTD with the reformulation that will set everything back considerably, If they don't release the interim results by close of play next Friday then will trading will be suspended?
Some good points raised but we still need 1801 to hit MTD before anything can start to move forwards let’s hope the reformulation worked, interestingly Sar did say “the final date for the interim results will be confirmed in the coming weeks” which we haven’t had yet? Maybe they are waiting for the BMS data later this month? Just so many possible scenarios for what lies ahead they could even let us delist end of April until everything is in place unlikely but this is AIM after all.
There are so many challenges and complexities where combination drugs are involved it’s not a simple process: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415086/
There have been many combinations for ours and other CHK1’s previously presented at AACR that amounted to nothing look at the Janssen combo that was pulled after all the pre clinical and CTA!
Still not expecting anything from Sierra if they don’t manage to on license and ultimately return SRA737 they will still pull some hefty royalties if it’s commercialised in the future. I think some here don’t realise the commercial value of Momelotinib or its P3 endpoints for its fast track that’s why they are 100% focused on Momelotinib.
It is a concern the bod seemed confident on the 15th December AGM Statement of the timeline for CTA I was expecting an RNS in Jan Feb for SDC-1801 reaching MTD and a build up in SP from there before the CTA / IND being filed in Q1.
“In recent months, we developed a new formulation, specifically designed to deliver higher exposure levels of the molecule, which we are now testing in additional toxicology studies, with a targeted completion date early in the New Year.
Data from these studies will form part of the planned Clinical Trial Application ("CTA"), which we aim to submit in the first quarter of 2021, and if approved would allow the start of clinical studies with SDC-1801. This would clearly be an important milestone for the Company”
There shouldn’t be a delay reaching Max Tox on the reformulation they knew what was needed and the timelines for submitting CTA/IND in Q1 one would have expected it to reach MTD in Feb with a fanfare RNS leading to CTA being submitted before end of Q1.
So what happens next if the reformulation hasn’t/can’t reach MTD? Surely they won’t reformulate again? It’s almost certainly holding up SDC-1802 from its long term tox studies until they know they have nailed the reformulation.
More like the half year update has been delayed because they haven’t reached MTD through problems or delays and are avoiding the forward looking statement until they have resolution…
The clue is in the RNS "We are encouraged to see yet another potential treatment" Sierra has no desire to fund or progress SRA737 as they are 100% focused and committed to to getting Momelotinib across the finish line and are only 12 months out from headline data which is most probably why the directors are buying now and the II's re shuffling